Regular Articlep16(MTS-1/CDKN2/INK4a) in Cancer Progression
References (261)
- et al.
Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition
Cell
(1999) Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia
Leuk. Res.
(2000)Expression of p16, Rb, and cyclin D1 gene products in oral and laryngeal squamous carcinoma: Biological and clinical implications
Hum. Pathol.
(1999)CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations
Am. J. Pathol.
(1998)- et al.
A genetic model for colorectal tumorigenesis
Cell
(1990) Candidate tumor-suppressor genes MTS1 (p16INK4A). and MTS2 (p15INK4B). display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias
Blood
(1994)The essentials of DNA methylation
Cell
(1992)Association of K-ras mutations with p16 methylation in human colon cancer
Gastroenterology
(1999)Genetic progression and divergence in pancreatic carcinoma
Am. J. Pathol.
(2000)Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies
Blood
(1996)
Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia
Blood
(1998)
Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: Potential prognostic implications
Blood
(2000)
Role of the INK4a locus in tumor suppression and cell mortality
Cell
(1996)
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF
Cell
(1997)
Requirements for cell cycle arrest by p16INK4a
Mol. Cell
(2000)
CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds
J. Invest. Dermatol.
(1998)
Two tracks but one race? Cancer genetics
Curr. Biol.
(1996)
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
Cell
(1998)
The INK4A/ARF locus and its two gene products
Curr. Opin. Genet. Dev.
(1999)
The serial cultivation of human diploid cell strains
Exp. Cell Res.
(1961)
Role of the p16 tumor suppressor gene in cancer
J. Clin. Oncol.
(1998)
Tumour-suppressor genes: Evolving definitions in the genomic age
Nat. Genet.
(1997)
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
Nature
(1993)
The p16INK4a/CDKN2A tumor suppressor and its relatives
Biochim. Biophys. Acta
(1998)
Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a
Nature
(1998)
Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d
Nature
(1998)
Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway
Genes Dev.
(1997)
Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: Prognostic significance of E2F-1 and p16INK4A
Leukemia
(2000)
An immunohistochemical study of p16, pRb, p21 and p53 proteins in human esophageal cancers
Anticancer Res.
(2000)
Expression of p16 and lack of pRB in primary small cell lung cancer
J. Pathol.
(1999)
Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers
Clin. Cancer Res.
(1999)
Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas
J. Neuropathol. Exp. Neurol.
(1998)
Expression of p16 induces transcriptional downregulation of the RB gene
Oncogene
(1998)
Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study
Int. J. Cancer
(1996)
Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB
Oncogene
(1994)
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
Nature
(1995)
Growth suppression by p16ink4 requires functional retinoblastoma protein
Proc. Natl. Acad. Sci. USA
(1995)
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nature
(1994)
A cell cycle regulator potentially involved in genesis of many tumor types
Science
(1994)
p16 gene in uncultured tumours
Nature
(1994)
Rates of p16 (MTS1). mutations in primary tumors with 9p loss
Science
(1994)
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
Nat. Genet.
(1995)
Deletion of p16 and p15 genes in brain tumors
Cancer Res.
(1994)
p16 alterations and deletion mapping of 9p21–p22 in malignant mesothelioma
Cancer Res.
(1994)
Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma
Cancer Res.
(1994)
Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2
Cancer Res.
(1995)
Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas—Relationship to amplification and mRNA levels of CDK4 and CCND1
Br. J. Cancer
(1995)
High frequency of p16 (CDKN2/MTS-1/INK4A). inactivation in head and neck squamous cell carcinoma
Cancer Res.
(1996)
Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor). gene in esophageal squamous cell carcinoma
Cancer Res.
(1994)
Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma
Cancer Res.
(1996)
Cited by (406)
Targeting mitochondrial dysfunction to salvage cellular senescence for managing neurodegeneration
2023, Advances in Protein Chemistry and Structural BiologyEndocervical neoplasia: Pathologic updates in diagnosis and prognosis
2022, Seminars in Diagnostic Pathologyp16 immunostaining in cytology specimens: its application, expression, interpretation, and challenges
2021, Journal of the American Society of CytopathologyCitation Excerpt :CDKN2A alterations that can affect p16 expression include promoter hyper-methylation, coding mutations, and deletions. These alterations have been shown in a wide range of cancers including pancreatic adenocarcinoma, melanoma, lymphomas, esophageal squamous cell carcinomas, gastric and colorectal cancers.25,26 Our data highlight the pitfalls present when utilizing p16 staining outside of the head and neck given the diversity of neoplasms that can express p16.
Retinoblastoma Genetics: Current Understanding and Future Directions
2020, Advances in Ophthalmology and Optometry
- 1
To whom correspondence and reprint requests should be addressed at the Department of Otolaryngology, Johns Hopkins University, 720 Rutland Avenue, Ross 818, Baltimore, MD 21205.
Copyright © 2001 Academic Press. All rights reserved.